Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2019

View Archived Issues

IKK-alpha and BRAF kinases implicated in DNA damage response can be targeted in cancer

Integrin alphaVbeta6 found to be an effective target for pancreatic ductal adenocarcinoma therapy

TRPV1 as a novel therapeutic target in type 2 diabetes mellitus

GM1 ganglioside is protective in alpha-synuclein model of Parkinson's disease

Shanghai Yingli Pharmaceutical identifies TGF-beta receptor type-1 inhibitors

Oxford University Innovation discloses RAS-effector protein interaction inhibitors

Enhancement of neuronal M-Type K+ currents prevents brain damage following traumatic brain injury

Mitochondrial metabolism promotes proteasome inhibitor resistance and sensitivity to elesclomol

Redx Pharma presents Rho-associated protein kinase inhibitors

LEF1 overexpression implicated in esophageal squamous cell carcinoma via TGF-beta signaling

Neutrophil extracellular traps help gallstones form

NFKBIL1 gene polymorphisms linked to autistic-like traits

Fujimoto Pharmaceutical describes new TNF-alpha production inhibitors

Microbiome boosts host defense against chlamydia

Medscienta presents new antiatherosclerotic agents

FDA approves Rinvoq for the treatment of moderate to severe rheumatoid arthritis

FDA approves the first new treatment in nearly a decade for patients with myelofibrosis

Scancell provided update on phase II study of SCIB-1 in patients with advanced melanoma

Recruitment ongoing in Janssen's first-in-human study of JNJ-74699157

Patient recruitment initiated in phase II study of TQ-B3101 in ROS1-positive NSCLC

Bird Rock Bio initiates phase II study of nimacimab in patients with diabetic gastroparesis

Fulcrum Therapeutics initiates phase IIb ReDUX4 study of losmapimod in FSHD